Drug Profile
Olinciguat - Cyclerion Therapeutics
Alternative Names: IW 1701Latest Information Update: 25 Apr 2024
Price :
$50
*
At a glance
- Originator Ironwood Pharmaceuticals
- Developer Cyclerion Therapeutics; Ironwood Pharmaceuticals
- Class Antifibrotics; Cardiovascular therapies; Fluorobenzenes; Isoxazoles; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Soluble guanylyl cyclase agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cardiovascular disorders
Highest Development Phases
- Phase I Cardiovascular disorders
- Discontinued Gastrointestinal disorders; Sickle cell anaemia
Most Recent Events
- 25 Apr 2024 Olinciguat is still in phase I trials for Cardiovascular disorders (In volunteers) in USA (PO) (Cyclerion Therapeutics Sec filling pipeline, April 2024)
- 31 Mar 2023 Olinciguat - Cyclerion Therapeutics is available for licensing as of 31 Mar 2023. https://www.cyclerion.com/pipeline/# 3774063
- 31 Mar 2023 Cyclerion Therapeutics has multiple patents approved worldwide for Olinciguat